Company Filing History:
1 out of 1 
1 out of 5 Years Active: 2006-2011
Title: Innovations of Markus A Rüegg in the Field of Muscular Dystrophy Treatment.
Introduction
Markus A Rüegg is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of medical science, particularly in the treatment of congenital muscular dystrophies. His innovative approach has the potential to improve the quality of life for many affected individuals.
Latest Patents
Rüegg holds a patent for a method of treating congenital muscular dystrophy caused by a mutation in the LAMA2 gene in mammals. The invention involves administering a therapeutically effective amount of a protein that includes at least one binding domain for laminin, one binding domain for α-dystroglycan, and one follastatin-like domain. This groundbreaking method represents a significant advancement in therapeutic options for this condition.
Career Highlights
Throughout his career, Markus A Rüegg has worked with prominent companies in the pharmaceutical industry. He has been associated with Santhera Pharmaceuticals (Schweiz) GmbH and Santhera Pharmaceuticals AG. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to innovative treatments.
Collaborations
One of his notable collaborators is Thomas Meier. Their partnership has likely fostered advancements in research and development within the realm of muscular dystrophy treatments.
Conclusion
Markus A Rüegg's contributions to the treatment of congenital muscular dystrophies highlight his innovative spirit and dedication to improving healthcare. His patent and career achievements reflect a commitment to advancing medical science for the benefit of patients.